IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: Confirmation No.: 6317

Mark VINCENT et al. Group Art Unit: 1636

Serial No.: 10/594,281 Examiner: Unassigned

Filed: September 26, 2006

For: ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF IN IMPROVING CANCER TREATMENT STRATEGIES

RESPONSE TO NOTICE TO FILE MISSING REQUIREMENTS & STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Notice to File Missing Requirements under 35 U.S.C. 371 in the U.S. mailed July 10, 2007, Applicants are submitting herewith a Declaration in compliance with 37 CFR §1.497(a) and (b) and a sequence listing as required by 37 CFR §1.821(c) and Statement thereof.

The sequence listing, filed herewith in accordance with 37 CFR §1.821(g), does not include new matter. Additionally, the content of the attached paper copy and the attached computer readable copy of the sequence listing, submitted in accordance with 37 CFR §1.821(c) and 37 CFR §1.821(e), respectively, are the same.

Docket No: 50098-002USNATL

Conclusion

The Commissioner is hereby authorized by this paper to charge any fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-3840. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).

Date: January 10, 2008

Proskauer Rose LLP

1001 Pennsylvania Avenue, NW

Suite 400, South

Washington, DC 20004 Telephone: 202.416.6800

Facsimile: 202.416.6899 CUSTOMER NO: 61263 Paul M. Booth

Attorney for Applicant Reg. No.: 40,244

Respectfully submitted,

Customer No. 61263